Peroxisome proliferator-activated receptors: Targets for the treatment of metabolic illnesses (Review)

• Published in: Molecular medicine reports Vol. 1; no. 3; pp. 317 - 324
• Main Authors: Moore-Carrasco, Rodrigo, Poblete Bustamante, Mauricio, González Guerra, Oscar, Leiva Madariaga, Elba, Mujica Escudero, Veronica, Aranguez Arellano, Claudio, Palomo, Iván
• Format: Journal Article
• Language: English
• Published: Greece 01.05.2008
• ISSN: 1791-2997; 1791-3004
• DOI: 10.3892/mmr.1.3.317

Peroxisome proliferator-activated receptors (PPARs) belong to a family of transcription factors of which three isotypes, PPARα, PPARδ (β) and PPARγ, are known. These play a central role in regulating intermediate metabolism and in incidences of inflammation. In recent years, a greater understanding of their mechanisms of action and their effects, principally in the management of cardiovascular disease, has been achieved. PPAR agonists, catalysts and agents have been used since the 1990s, when it was confirmed that fibrates possess lipid modifying properties when selectively activating PPARα. In addition, thiazolidinediones, structures analogous to fibrates, showed PPARγ activity with an insulin-sensitizing effect, leading to their use in the control and even prevention of diabetes mellitus type 2. Currently, studies are oriented to the development of agents that activate multiple PPAR isoforms - not only dual (PPARα/γ), but also PPAR panagonists (α/γ/δ). The purpose of this review is to explain the mechanisms of the molecular action and the effects of PPAR agonists, and also to analyze existing and current studies concerning their use in cardiovascular and metabolic illnesses.